Tag: Janus kinase (JAK) inhibitor

1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the placebo group. 2. The proportion of patients with treatment-related side effects was similar between filgotinib 100 mg, filgotinib 200 mg, and placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ulcerative colitis (UC)...
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib was associated with more frequent adverse events than adalimumab. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriatic arthritis (PA) is an autoimmune condition primarily affecting the skin and joints. The condition is...
1. Upadacitinib was superior to abatacept in achieving remission at 12 weeks for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDs). 2. Upadacitinib was associated with more severe adverse events compared to abatacept. Evidence Rating Level: 1 (Excellent) Study Rundown: Abatacept treats rheumatoid arthritis by inhibiting T-cell proliferation and...